AE Wealth Management LLC Boosts Stake in Abbott Laboratories $ABT

AE Wealth Management LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 20.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,504 shares of the healthcare product maker’s stock after purchasing an additional 11,264 shares during the quarter. AE Wealth Management LLC’s holdings in Abbott Laboratories were worth $8,774,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Charles Schwab Trust Co increased its stake in shares of Abbott Laboratories by 109.8% during the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after acquiring an additional 15,394 shares during the period. Asset Management One Co. Ltd. increased its position in shares of Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after purchasing an additional 19,966 shares during the period. Nordea Investment Management AB raised its stake in shares of Abbott Laboratories by 6.1% in the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after buying an additional 18,974 shares in the last quarter. Seaview Investment Managers LLC bought a new position in Abbott Laboratories during the second quarter valued at about $11,068,000. Finally, iA Global Asset Management Inc. grew its holdings in Abbott Laboratories by 94.0% during the third quarter. iA Global Asset Management Inc. now owns 144,062 shares of the healthcare product maker’s stock worth $19,296,000 after acquiring an additional 69,803 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the subject of several research reports. Royal Bank Of Canada reduced their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. Argus reduced their price objective on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday. Wells Fargo & Company lifted their target price on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. Finally, Jefferies Financial Group increased their price target on shares of Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $140.75.

Abbott Laboratories Price Performance

NYSE ABT opened at $109.31 on Friday. The company has a market cap of $190.08 billion, a P/E ratio of 29.39, a P/E/G ratio of 1.69 and a beta of 0.72. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The company has a fifty day simple moving average of $122.77 and a 200 day simple moving average of $127.49.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.